Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Public ClinicalTrials.gov record NCT00096473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period
Study identification
- NCT ID
- NCT00096473
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 229 participants
Conditions and interventions
Conditions
Interventions
- Donepezil hydrochloride Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2000
- Primary completion
- May 31, 2005
- Completion
- Aug 31, 2005
- Last update posted
- Mar 31, 2011
2001 – 2005
United States locations
- U.S. sites
- 28
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Northport | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Sun City | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | North Miami | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Springfield | Massachusetts | — | — |
| Not listed | Long Branch | New Jersey | — | — |
| Not listed | Piscataway | New Jersey | — | — |
| Not listed | New Hyde Park | New York | — | — |
| Not listed | Greenville | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Centerville | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Medford | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Jenkintown | Pennsylvania | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00096473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00096473 live on ClinicalTrials.gov.